Asthma  >>  Flutiform (fluticasone/formoterol)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
NCT00657774: A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands

Completed
1
160
US
FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg, Placebo
SkyePharma AG, Abbott
Asthma
09/08
09/08
NCT02403713: A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers

Completed
1
125
Europe
Fluticasone/formoterol BAI, Formoterol, Fluticasone/formoterol PMDI without spacer, Fluticasone/formoterol PMDI with spacer, Fluticasone/formoterol PMDI without spacer low dose
Mundipharma Research Limited
Asthma
10/14
09/15
ChiCTR1800019111: An open-label, single-dose and single- plus multiple-dose study to assess the pharmacokinetic profile of FLUTIFORM pMDI 50/5 μg (100/10 μg total dose), 125/5 μg (250/10 μg total dose), and 250/10 μg (500/20 μg total dose) in healthy Chinese subjects

Recruiting
1
36
 
FLUTIFORM pMDI single-dose administration (50/5 μg, 125/5 μg, and 250/10 μg) and multiple-dose administration (250/10 μg)
West China Hospital, Sichuan University; Mundipharma (China) Pharmaceutical Co. Ltd, Mundipharma (China) Pharmaceutical Co. Ltd
Asthma
 
 

Download Options